TCIM
PTCT icon

TIAA CREF Investment Management’s PTC Therapeutics PTCT Stock Holding History

TIAA CREF Investment Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$8.2M Buy
217,807
+5,819
+3% +$195K 0.01% 1139
2018
Q4 		$7.28M Sell
211,988
-21,304
-9% -$766K 0.01% 1136
2018
Q3 		$11M Sell
233,292
-8,103
-3% -$335K 0.01% 1059
2018
Q2 		$8.14M Sell
241,395
-5,861
-2% -$183K 0.01% 1282
2018
Q1 		$6.69M Buy
247,256
+120,816
+96% +$3.06M ﹤0.01% 1374
2017
Q4 		$2.11M Buy
126,440
+25,111
+25% +$425K ﹤0.01% 2099
2017
Q3 		$2.03M Buy
101,329
+10,373
+11% +$203K ﹤0.01% 2157
2017
Q2 		$1.67M Sell
90,956
-5,362
-6% -$72.2K ﹤0.01% 2293
2017
Q1 		$948K Buy
96,318
+2,774
+3% +$33.6K ﹤0.01% 2533
2016
Q4 		$1.02M Sell
93,544
-13,258
-12% -$139K ﹤0.01% 2517
2016
Q3 		$1.5K Sell
106,802
-24,622
-19% -$200K ﹤0.01% 2336
2016
Q2 		$923K Buy
131,424
+22,167
+20% +$163K ﹤0.01% 2549
2016
Q1 		$704K Sell
109,257
-22,144
-17% -$384K ﹤0.01% 2649
2015
Q4 		$4.26M Sell
131,401
-4,299
-3% -$127K ﹤0.01% 1668
2015
Q3 		$3.62M Sell
135,700
-3,298
-2% -$141K ﹤0.01% 1757
2015
Q2 		$6.69M Buy
138,998
+41,674
+43% +$2.43M ﹤0.01% 1456
2015
Q1 		$5.92M Buy
97,324
+1,522
+2% +$92.9K ﹤0.01% 1512
2014
Q4 		$4.96M Sell
95,802
-2,616
-3% -$115K ﹤0.01% 1631
2014
Q3 		$4.33M Sell
98,418
-1,268
-1% -$39.7K ﹤0.01% 1723
2014
Q2 		$2.61M Buy
99,686
+59,768
+150% +$1.28M ﹤0.01% 2136
2014
Q1 		$1.04M Buy
39,918
+12,730
+47% +$342K ﹤0.01% 2623
2013
Q4 		$461K Buy
27,188
+3,450
+15% +$60.6K ﹤0.01% 2984
2013
Q3 		$509K Buy
+23,738
New +$413K ﹤0.01% 2933

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TIAA CREF Investment Management's PTCT Position: Q1 2019 in Review

TIAA CREF Investment Management increased its PTC Therapeutics (PTCT) stake by 2.7% in Q1 2019, buying an estimated $195K and bringing the position to 217,807 shares worth $8.2M. The position accounts for 0.01% of the portfolio, ranked #1139.

TIAA CREF Investment Management first reported a position in PTCT in Q3 2013 and has held it in 23 quarters since. The position peaked at $11M in Q3 2018. 174 funds tracked by Wall St. Rank hold PTCT as of Q1 2019.

  • TIAA CREF Investment Management held 217,807 shares of PTC Therapeutics worth $8.2M as of Q1 2019.
  • TIAA CREF Investment Management bought 5,819 PTC Therapeutics shares in Q1 2019, an estimated $195K.
  • PTC Therapeutics made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1139 holding.
  • TIAA CREF Investment Management first reported a position in PTC Therapeutics in Q3 2013 and has held it in 23 quarters since.
  • TIAA CREF Investment Management's PTC Therapeutics position peaked at $11M in Q3 2018.
  • 174 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.